title: Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation.
abstract: Chordoid meningioma, World Health Organization grade II, is an uncommon variant of meningioma with a propensity for aggressive behavior and increased likelihood of recurrence. As such, recognition of this entity is important in cases that show similar morphologic overlap with other chondroid/myxoid neoplasms that can arise within or near the central nervous system. A formal comparison of the immunohistochemical features of chordoid meningioma versus tumors with significant histologic overlap has not been previously reported. In this study, immunohistochemical staining was performed with antibodies against D2-40, S100, pankeratin, epithelial membrane antigen (EMA), brachyury, and glial fibrillary acidic protein (GFAP) in 4 cases of chordoid glioma, 6 skeletal myxoid chondrosarcomas, 10 chordoid meningiomas, 16 extraskeletal myxoid chondrosarcoma, 18 chordomas, 22 low-grade chondrosarcomas, and 27 enchondromas. Staining extent and intensity were evaluated semiquantitatively and mean values for each parameter were calculated. Immunostaining with D2-40 showed positivity in 100% of skeletal myxoid chondrosarcomas, 96% of enchondromas, 95% of low-grade chondrosarcomas, 80% of chordoid meningiomas, and 75% of chordoid gliomas. Staining with S100 demonstrated diffuse, strong positivity in all (100%) chordoid gliomas, skeletal myxoid chondrosarcomas, low-grade chondrosarcomas, and enchondromas, 94% of chordomas, and 81% of extraskeletal myxoid chondrosarcomas, with focal, moderate staining in 40% of chordoid meningiomas. Pankeratin highlighted 100% of chordoid gliomas and chordomas, 38% of extraskeletal myxoid chondrosarcomas, and 20% of chordoid meningiomas. EMA staining was positive in 100% of chordoid gliomas, 94% of chordomas, 90% of chordoid meningiomas, and 25% of extraskeletal myxoid chondrosarcomas. Brachyury was positive only in the chordomas (100%), whereas GFAP was positive only in the chordoid gliomas (100%). EMA was the most effective antibody for differentiating chordoid meningioma from skeletal myxoid chondrosarcoma, low-grade chondrosarcoma, and enchondroma, whereas D2-40 was the most effective antibody for differentiating chordoid meningioma from extraskeletal myxoid chondrosarcoma and chordoma. Our findings demonstrate that in conjunction with clinical and radiographic findings, immunohistochemical evaluation with a panel of D2-40, EMA, brachyury, and GFAP is most useful in distinguishing chordoid meningioma from chordoid glioma, skeletal myxoid chondrosarcoma, extraskeletal myxoid chondrosarcoma, chordoma, low-grade chondrosarcoma, and enchondroma. A lack of strong, diffuse S100 reactivity may also be useful in excluding chordoid meningioma. Among the neoplasms evaluated, brachyury and GFAP proved to be both sensitive and specific markers for chordoma and chordoid glioma, respectively. Of note, this study is the first to characterize the D2-40 immunoprofile in extraskeletal myxoid chondrosarcoma, results that could be of utility in differential diagnostic assessment.
authors.affiliation: Department of Pathology, Stanford University, Stanford, CA, USA. asangoi2@yahoo.com
authors.forename: Ankur R
authors.initials: AR
authors.lastname: Sangoi
authors.forename: Mohanpal S
authors.initials: MS
authors.lastname: Dulai
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Beck
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Brat
authors.forename: Hannes
authors.initials: H
authors.lastname: Vogel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D014408:Biomarkers, Tumor / Q000032:analysis*; D002648:Child; D002812:Chondroma / Q000737:chemistry / Q000473:pathology; D002813:Chondrosarcoma / Q000737:chemistry / Q000473:pathology; D002817:Chordoma / Q000737:chemistry* / Q000473:pathology*; D003937:Diagnosis, Differential; D005260:Female; D005326:Fetal Proteins / Q000032:analysis; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis; D005910:Glioma / Q000737:chemistry / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis; D008297:Male; D008577:Meningeal Neoplasms / Q000737:chemistry* / Q000473:pathology*; D008579:Meningioma / Q000737:chemistry* / Q000473:pathology*; D008875:Middle Aged; D018396:Mucin-1 / Q000032:analysis; D011237:Predictive Value of Tests; D009418:S100 Proteins / Q000032:analysis; D020825:T-Box Domain Proteins / Q000032:analysis; D055815:Young Adult; D000098908:Brachyury Protein
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D014408:Biomarkers, Tumor; D005326:Fetal Proteins; D005904:Glial Fibrillary Acidic Protein; D007633:Keratins; D018396:Mucin-1; D009418:S100 Proteins; D020825:T-Box Domain Proteins; D000098908:Brachyury Protein; C500987:monoclonal antibody D2-40